Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,237
Total Claims
$1.2M
Drug Cost
641
Beneficiaries
$1,846
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+31%
Cost per patient vs peers
$1,846 vs $1,411 avg
+24%
Brand preference vs peers
13.2% vs 10.6% avg
Brand vs Generic
Brand: 1,336 claims · $957K
Generic: 8,808 claims · $224K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 85 | $110K |
| Empagliflozin | 82 | $109K |
| Semaglutide | 78 | $95K |
| Semaglutide | 53 | $79K |
| Linagliptin | 60 | $55K |
| Budesonide/Formoterol Fumarate | 122 | $51K |
| Dulaglutide | 48 | $51K |
| Apixaban | 33 | $46K |
| Sacubitril/Valsartan | 26 | $33K |
| Finerenone | 22 | $32K |
| Mirabegron | 28 | $22K |
| Sitagliptin Phosphate | 13 | $21K |
| Denosumab | 13 | $20K |
| Rivaroxaban | 13 | $19K |
| Icosapent Ethyl | 24 | $18K |
Prescribing Profile
Patient Profile
77
Avg Age
60%
Female
1.13
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data